Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs United States Copper Index Fund (CPER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs United States Copper Index Fund — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while United States Copper Index Fund trades at $37.8. The key difference: United States Copper Index Fund is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CPER | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $491.22 | $40.60 |
52-Week Low | $278.09 | $27.21 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CPER (United States Copper Index Fund) trades at $37.99, up 0.64% with a bullish technical signal from moving averages. The ETF provides exposure to copper futures, benefiting from industrial demand driven by electrification and AI infrastructure. Recent news highlights copper's outperformance versus gold and silver in 2026, with supply constraints and strong demand supporting prices.
The outlook remains positive given structural demand trends, though risks include global manufacturing weakness and commodity price volatility. Analyst sentiment favors copper's role in the energy transition, but investors should monitor economic indicators that could impact industrial metal demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →
